改良CAG方案治疗成人复发性急性髓系白血病的临床研究

本研究观察改良的阿糖胞苷、阿柔比星及粒细胞集落刺激因子联合化疗（CAG）方案治疗复发性急性髓系白血病（AML）的临床疗效及其不良反应。应用改良的CAG方案治疗复发性急性髓系白血病17例。本组病例中阿柔比星静脉应用时间为7天，完成1疗程后评估疗效及副作用，不缓解者退出观察，有效者则继续接受1个疗程化疗。结果表明：17例AML患者中8例获得完全缓解（CR），5例获得部分缓解（PR），CR率为47．06％，PR率为29．41％，总有效率为76．47％。大部分患者有骨髓抑制等可耐受的不良反应。结论：CAG方案治疗复发难治性AML的疗效较好，为部分患者行异基因骨髓移植赢得了机会，但其长期维持治疗的疗效有待进一步研究。

Clinical Research of Modified CAG Regimen for the Treatment of Relapsed Acute Myeloid Leukemia

The objective of study was to observe the efficacy and adverse events of modified CAG regimen in treating patients with relapsed acute myeloid leukemia. CAG regimen with prolongation of aclarubicin up to 7 days were used to treat 17 cases of relapsed acute myeloid. After 1 course of chemotherapy, the efficacy and adverse events were evaluated, patients who did not achive remission were excluded from this regimen, patients who achieved remission were contineously given 1 course of CAG regimen. The results showed that out of 17 case 8 patients achived complete remission （CR, 47.06% ） and 5 patients achived patial remission （PR, 29.14% ）. Most of these cases had slight adverse events which mainly were marrow suppression that could be tolerated, overall surviral was 76.47%. In conclussion, treatment for relapsed acute myeloid leukemia with modified CAG regiment is safe and effective, and can provide conditions for allo-hematopoietic stem cell transplantation, but its long term efficacy needs to further study.